HC Wainwright Rates Ionis Pharmaceuticals (IONS) buy

On June 25, 2026, analyst Mitchell S. Kapoor from HC Wainwright reiterated a Buy rating on Ionis Pharmaceuticals, Inc. (IONS) on the NasdaqGS. The firm set a price target of $130.00, suggesting significant potential for the stock to climb from its recent levels. This move comes as the biotechnology company continues to roll out its portfolio of RNA-based treatments for rare and genetic diseases.

Growth Potential in the Analyst View

The decision by HC Wainwright to stick with a $130.00 price target reflects a positive outlook on the company's long-term value. While the stock has seen various target adjustments from other firms, this reiteration stands as one of the more optimistic projections on Wall Street. Following this report, other analysts have also weighed in. On September 24, 2026, HC Wainwright & Co. again reiterated a Buy rating with a $100.00 target. More recently, on October 15, 2026, UBS upgraded the stock from a previous stance to a Buy, raising its price target to $88.00 from $46.00.

Ionis Stock Price and Market Trends

On Thursday, the stock was trading around $81.18. This price point puts Ionis in a relatively strong position, as it is currently trading well above its 52-week low of $44.20. The stock has also stayed above its 200-day moving average of $72.00, which is often seen as a sign of steady upward momentum. With a market value of approximately $7.46 billion, the company remains a major player in the biotech sector despite not yet being profitable.

Recent Earnings and Revenue Performance

Ionis reported revenue of about $874.09 million in its most recent financial data, though it saw a revenue growth decline of 40.7%. The company is currently operating at a loss, with a net margin of -64.6% and a return on equity of -105.5%. Because it is not yet profitable, Ionis does not have a standard P/E ratio, though its forward P/E is listed at -40.37. Investors are looking toward the next earnings report, which is expected on November 4, 2026, to see how new drug launches are impacting the bottom line.

Executives Show Confidence with Stock Purchases

Recent activity from company leaders suggests internal confidence in the firm's direction. On June 26, 2026, Eugene Schneider, the Executive Vice President of Clinical Development, bought 26,000 shares at an average price of $60.89, a trade worth roughly $1.58 million. On the same day, Joseph Baroldi, the Chief Business Officer, purchased 5,635 shares at an average price of $49.19, totaling about $277,181. Neither of these trades was made under a pre-planned Rule 10b5-1 trading schedule.

Mixed Sentiment from Wall Street Analysts

The broader analyst community shows a variety of opinions on Ionis. While HC Wainwright is bullish, JP Morgan maintained an Overweight rating on September 22, 2026, but lowered its target to $70.00. Guggenheim also trimmed its target to $80.00 on September 15, while Morgan Stanley remains positive with an Overweight rating and a $104.00 target. On the more cautious side, Goldman Sachs maintained a Neutral rating with a $56.00 target in early September. Overall, the consensus among 22 analysts is a Hold, with an average price target of $83.82.

RNA-Targeted Medicine Specialist

Ionis Pharmaceuticals is a California-based biotech firm that focuses on creating medicines that target RNA to treat diseases that traditional drugs often can't reach. Their products cover a wide range of conditions, from heart disease and neurological disorders to rare genetic issues like spinal muscular atrophy. The company often works with large partners like AstraZeneca, Biogen, and GSK to bring these complex treatments to patients around the world.

What to Watch at Ionis Pharmaceuticals, Inc.

Investors should keep an eye on the upcoming November 4, 2026, earnings date for updates on the company's clinical trials and commercial sales. While analyst targets like the $130.00 from HC Wainwright provide a look at potential future value, they are projections and not guarantees of where the stock will trade. Further disclosures of executive stock trades or new partnership agreements could also influence the stock's path in the coming months.